A folate receptor-targeted lipoplex delivering interleukin-15 gene for colon cancer immunotherapy
Metrics: PDF 1677 views | HTML 2793 views | ?
Xiao Liang1, Min Luo1, Xia-Wei Wei1, Cui-Cui Ma1, Yu-Han Yang1, Bin Shao1, Yan-Tong Liu1, Ting Liu1, Jun Ren1, Li Liu1, Zhi-Yao He1, Yu-Quan Wei1
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China
Zhi-Yao He, email: [email protected]
Yu-Quan Wei, email: [email protected]
Keywords: interleukin-15, folate receptor α, colon cancer, immunotherapy, gene therapy
Received: January 23, 2016 Accepted: June 16, 2016 Published: July 11, 2016
Interleukin-15 has been implicated as a promising cytokine for cancer immunotherapy, while folate receptor α (FRα) has been shown to be a potentially useful target for colon cancer therapy. Herein, we developed F-PLP/pIL15, a FRα-targeted lipoplex loading recombinant interleukin-15 plasmid (pIL15) and studied its antitumor effects in vivo using a CT26 colon cancer mouse model. Compared with control (normal saline) treatment, F-PLP/pIL15 significantly suppressed tumor growth in regard to tumor weight (P < 0.001) and reduced tumor nodule formation (P < 0.001). Moreover, when compared to other lipoplex-treated mice, F-PLP/pIL15-treated mice showed higher levels of IL15 secreted in the serum (P < 0.001) and ascites (P < 0.01). These results suggested that the targeted delivery of IL15 gene might be associated with its in vivo antitumor effects, which include inducing tumor cell apoptosis, inhibiting tumor proliferation and promoting the activation of immune cells such as T cells and natural killer cells. Furthermore, hematoxylin and eosin staining of vital organs following F-PLP/pIL15 treatment showed no detectable toxicity, thus indicating that intraperitoneal administration may be a viable route of delivery. Overall, these results suggest that F-PLP/pIL15 may serve as a potential targeting preparation for colon cancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.